Clinical Trial Update: Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload [Phase 4]

View source ↗

Summary

Phase 4 trial assessing the efficacy and safety of deferasirox in patients with myelodysplastic syndrome and transfusion-dependent iron overload has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes
• Transfusion-dependent Iron Overload

Drugs mentioned

• Exjade (deferasirox)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Myelodysplastic Syndromes, Transfusion Dependent Iron Overload | Phase 4 | Status: COMPLETED